GLP‑1 Medications & the Gut Microbiome – What We Know So Far

GLP‑1 medications like liraglutide, exenatide, dulaglutide, and semaglutide are best known for supporting weight loss, improving blood sugar, and protecting the heart. But there's growing interest in another surprising target: the gut microbiome.

In April 2025, a comprehensive systematic review published in Nutrients explored how these GLP‑1 drugs influence gut bacteria—and what that might mean for metabolic health, inflammation, and long-term outcomes.

What the Study Looked At

The study, conducted by Gofron, Wasilewski, and Małgorzewicz (2025), reviewed 38 human and animal studies on the effects of GLP‑1 analogs on gut microbiota composition, richness, and diversity.

Citation: Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025 Apr 9;17(8):1303. doi: 10.3390/nu17081303.

Key Findings: GLP‑1s and Gut Bacteria Changes

1. Liraglutide (Saxenda, Victoza)

• Promoted growth of beneficial bacteria, especially those linked to better metabolic health
• Increased microbiota richness and diversity in most models

2. Exenatide and Exendin‑4 (Byetta)

• Animal studies: Boosted bacteria associated with improved metabolism
• Human studies: Mixed results; some beneficial microbes increased, but so did inflammation-associated genera

3. Dulaglutide (Trulicity)

• Showed increased levels of Bacteroides, Akkermansia, and Ruminococcus—three genera often tied to better metabolic outcomes
• Positive influence on gut ecosystem stability

4. Semaglutide (Ozempic, Wegovy)

• Boosted levels of Akkermansia muciniphila, a bacteria linked to glucose regulation and reduced body fat
• However, overall microbial diversity dropped, raising questions about long-term gut health

What Do These Changes Mean?

While GLP‑1 medications do seem to shift the gut microbiota, the clinical implications are still unclear. In general:

• More Akkermansia and Ruminococcus is a good sign—they help regulate metabolism, reduce inflammation, and protect the gut lining
• Less microbial diversity (as seen with semaglutide) could signal potential drawbacks or nutrient absorption issues over time
• Inflammatory bacteria increases in some human models call for closer monitoring

Why This Matters for You

The gut microbiome isn't just a passive passenger—it influences your immune system, blood sugar, mental health, and inflammation levels. That's why it's worth caring for your gut alongside medications like GLP‑1s, so you don't just lose weight—but gain resilience.

We recommend:

• Probiotic and prebiotic support for those on long-term GLP‑1s
• Anti-inflammatory nutrition plans focused on fiber-rich, fermented, and polyphenol-packed foods

Conclusion

GLP‑1 medications reshape the gut—but how, and to what effect, depends on the drug, your genetics, your diet, and more. Early findings suggest positive shifts in some beneficial bacteria, but we need more studies to understand long-term microbiome implications.